Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas To Market Pain Patch Of NeurogesX Of U.S.

This article was originally published in PharmAsia News

Executive Summary

Astellas Pharma has agreed to market U.S.-based NeurogesX's patch for relieving pain in Europe, Africa and the Middle East. The drug is Qutenza (capsaicin), which has European Union approval, but is not yet approved in the United States. Under the agreement, Astellas is to pay NeurogesX $42 million upfront for marketing rights. The drug patch is expected to be launched in the first half of next year. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts